Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cobolimab

A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, cobolimab binds to TIM-3 expressed on certain T cells, including tumor infiltrating lymphocytes (TILs). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which results in a reduction in tumor growth. TIM-3, a transmembrane protein and immune checkpoint receptor, is associated with tumor-mediated immune suppression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TIM3 checkpoint inhibitor TSR-022
anti-TIM3 monoclonal antibody TSR-022
Code name:TSR-022
Chemical structure:immunoglobulin G4, anti-(hepatitis A virus cellular receptor 2 (havcr2)) (humanized clone ABT2 gamma4-chain), disulfide with humanized clone ABT2 kappa-chain, dimer
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search